{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["41(36)"],"submitter":["Vergote I"],"pubmed_abstract":["Purpose
Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).Methods
This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or s"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["5536-5549"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10730069"],"repository":["biostudies-literature"],"pubmed_title":["Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study."],"pmcid":["PMC10730069"],"pubmed_authors":["Denys HG","Sadozye A","Madsen K","Ghamande S","Collins DC","Cibula D","Chisamore MJ","Scambia G","Mondrup Andreassen C","Gort E","Van Nieuwenhuysen E","Baurain JF","Banerjee S","Monk BJ","Boere IA","Ottevanger N","Lorusso D","Eaton L","Vergote I","Randall LM","O'Cearbhaill RE","Soumaoro I","Westermann A","Kose F","Mathews CA","Gennigens C","Zikan M","Forget F","Tewari KS","Jackson AL","Viana Nicacio L"],"additional_accession":[]},"is_claimable":false,"name":"Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.","description":"Purpose
Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).Methods
This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or s","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-26T20:33:43.021Z","creation":"2025-04-06T16:26:41.744Z"},"accession":"S-EPMC10730069","cross_references":{"pubmed":["37651655"],"doi":["10.1200/JCO.23.00720"]}}